{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:13:19Z","timestamp":1786979599412,"version":"build-2736575974"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:00:00Z","timestamp":1779926400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:00:00Z","timestamp":1779926400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Khon Kaen University (Fundamental Fund 2568), funded by the National Science, Research, and Innovation Fund"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Chem Res"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s00044-026-03578-7","type":"journal-article","created":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T09:29:49Z","timestamp":1779960589000},"page":"1201-1221","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Exploring new quinoxaline, quinoline, and naphthalene carboxamides as HDAC-targeted anticancer agents: Cytotoxicity, enzymatic HDAC evaluation, and in silico studies"],"prefix":"10.1007","volume":"35","author":[{"given":"Jariya","family":"Jampahom","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiratthakan","family":"Prathumchat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siripit","family":"Pitchuanchom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chadaporn","family":"Leerat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narissara","family":"Namwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thanaset","family":"Senawong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jantana","family":"Yahuafai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwanjai","family":"Kanokmedhakul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chanokbhorn","family":"Phaosiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mongkol","family":"Nontakitticharoen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,28]]},"reference":[{"issue":"3","key":"3578_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"3578_CR2","doi-asserted-by":"publisher","first-page":"a018713","DOI":"10.1101\/cshperspect.a018713","volume":"6","author":"E Seto","year":"2014","unstructured":"Seto E, Yoshida M. Erasers of histone acetylation: The histone deacetylase enzymes. Cold Spring Harb Perspect Biol. 2014;6(4):a018713. https:\/\/doi.org\/10.1101\/cshperspect.a018713.","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"10","key":"3578_CR3","doi-asserted-by":"publisher","first-page":"4409","DOI":"10.1016\/j.ejmech.2010.06.024","volume":"45","author":"S Thangapandian","year":"2010","unstructured":"Thangapandian S, John S, Sakkiah S, Lee KW. Ligand and structure based pharmacophore modeling to facilitate novel histone deacetylase 8 inhibitor design. Eur J Med Chem. 2010;45(10):4409\u201317. https:\/\/doi.org\/10.1016\/j.ejmech.2010.06.024.","journal-title":"Eur J Med Chem"},{"key":"3578_CR4","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.1016\/j.csbj.2023.03.016","volume":"21","author":"H Jo","year":"2023","unstructured":"Jo H, Shim K, Kim HU, Jung HS, Jeoung D. HDAC2 as a target for developing anti-cancer drugs. Comput Struct Biotechnol J. 2023;21:2048\u201357. https:\/\/doi.org\/10.1016\/j.csbj.2023.03.016.","journal-title":"Comput Struct Biotechnol J"},{"issue":"21","key":"3578_CR5","doi-asserted-by":"publisher","first-page":"3372","DOI":"10.1002\/cncr.34974","volume":"129","author":"R Parveen","year":"2023","unstructured":"Parveen R, Harihar D, Chatterji BP. Recent histone deacetylase inhibitors in cancer therapy. Cancer. 2023;129(21):3372\u201380. https:\/\/doi.org\/10.1002\/cncr.34974.","journal-title":"Cancer"},{"issue":"3","key":"3578_CR6","doi-asserted-by":"publisher","first-page":"424","DOI":"10.7150\/ijms.30154","volume":"16","author":"Q Zhang","year":"2019","unstructured":"Zhang Q, Wang S, Chen J, Yu Z. Histone deacetylases (HDACs) guided novel therapies for T-cell lymphomas. Int J Med Sci. 2019;16(3):424\u201342. https:\/\/doi.org\/10.7150\/ijms.30154.","journal-title":"Int J Med Sci"},{"issue":"3","key":"3578_CR7","doi-asserted-by":"publisher","first-page":"185","DOI":"10.5582\/irdr.2016.01024","volume":"5","author":"X Lu","year":"2016","unstructured":"Lu X, Ning Z, Li Z, Cao H, Wang X. Development of chidamide for peripheral T-cell lymphoma, the first orphan drug approved in China. Intracable Rare Dis Res. 2016;5(3):185\u201391. https:\/\/doi.org\/10.5582\/irdr.2016.01024.","journal-title":"Intracable Rare Dis Res"},{"issue":"7","key":"3578_CR8","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1038\/sj.leu.2403388","volume":"18","author":"DM Lucas","year":"2004","unstructured":"Lucas DM, Davis ME, Parthun MR, Mone AP, Kitada S, Cunningham KD, et al. The histone deacetylase inhibitor MS\u2013275 induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia cells. Leukemia. 2004;18(7):1207\u201314. https:\/\/doi.org\/10.1038\/sj.leu.2403388.","journal-title":"Leukemia"},{"issue":"6","key":"3578_CR9","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1517\/13543784.2011.577737","volume":"20","author":"Y Boumber","year":"2011","unstructured":"Boumber Y, Younes A, Garcia-Manero G. Mocetinostat (MGCD0103): A review of an isotype-specific histone deacetylase inhibitor. Expert Opin Investig Drugs. 2011;20(6):823\u20139. https:\/\/doi.org\/10.1517\/13543784.2011.577737.","journal-title":"Expert Opin Investig Drugs"},{"issue":"9","key":"3578_CR10","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1016\/j.leukres.2012.03.003","volume":"36","author":"A Quint\u00e1s-Cardama","year":"2012","unstructured":"Quint\u00e1s-Cardama A, Kantarjian H, Estrov Z, Borthakur G, Cortes J, Verstovsek S. Therapy with the histone deacetylase inhibitor pracinostat for patients with myelofibrosis. Leuk Res. 2012;36(9):1124\u20137. https:\/\/doi.org\/10.1016\/j.leukres.2012.03.003.","journal-title":"Leuk Res"},{"issue":"1","key":"3578_CR11","doi-asserted-by":"publisher","first-page":"2082","DOI":"10.1038\/s41598-025-86007-w","volume":"15","author":"TS Iveland","year":"2025","unstructured":"Iveland TS, Hagen L, de Sousa MML, Liabakk NB, Aas PA, Sharma A, et al. Cytotoxic mechanisms of pemetrexed and HDAC inhibition in non-small cell lung cancer cells involving ribonucleotides in DNA. Sci Rep. 2025;15(1):2082. https:\/\/doi.org\/10.1038\/s41598-025-86007-w.","journal-title":"Sci Rep"},{"key":"3578_CR12","doi-asserted-by":"publisher","first-page":"114602","DOI":"10.1016\/j.ejmech.2022.114602","volume":"240","author":"R Sharma","year":"2022","unstructured":"Sharma R, Chatterjee E, Mathew J, Sharma S, Rao NV, Pan CH, et al. Accommodation of ring C expanded deoxyvasicinone in the HDAC inhibitory pharmacophore culminates into a tractable anti-lung cancer agent and pH-responsive nanocarrier. Eur J Med Chem. 2022;240:114602. https:\/\/doi.org\/10.1016\/j.ejmech.2022.114602.","journal-title":"Eur J Med Chem"},{"key":"3578_CR13","doi-asserted-by":"publisher","first-page":"1544666","DOI":"10.3389\/fphar.2025.1544666","volume":"16","author":"E Chatterjee","year":"2025","unstructured":"Chatterjee E, Sharma R, Dey B, Singh H, Naik A, Basak S, et al. Anticancer activity of RM-3-22: a TAZQ-based hydroxamic acid derivative targeting NSCLC in vitro and in vivo. Front Pharmacol. 2025;16:1544666. https:\/\/doi.org\/10.3389\/fphar.2025.1544666.","journal-title":"Front Pharmacol"},{"issue":"1","key":"3578_CR14","doi-asserted-by":"publisher","first-page":"e1900427","DOI":"10.1002\/cbdv.201900427","volume":"17","author":"F Yang","year":"2020","unstructured":"Yang F, Zhao N, Hu Y, Jiang C, Zhang H. The development process: from SAHA to hydroxamate HDAC inhibitors with branched CAP region and linear linker. Chem Biodivers. 2020;17(1):e1900427. https:\/\/doi.org\/10.1002\/cbdv.201900427.","journal-title":"Chem Biodivers"},{"issue":"6","key":"3578_CR15","doi-asserted-by":"publisher","first-page":"e1800027","DOI":"10.1002\/cbdv.201800027","volume":"15","author":"DT Hieu","year":"2018","unstructured":"Hieu DT, Anh DT, Hai PT, Cuong PQ, Nam NH, Oanh DTK, et al. Quinazoline-based hydroxamic acids: design, synthesis, and evaluation of histone deacetylase inhibitory effects and cytotoxicity. Chem Biodivers. 2018;15(6):e1800027. https:\/\/doi.org\/10.1002\/cbdv.201800027.","journal-title":"Chem Biodivers"},{"key":"3578_CR16","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.ejmech.2017.11.064","volume":"143","author":"S Tariq","year":"2018","unstructured":"Tariq S, Somakala K, Amir Mohd. Quinoxaline: An insight into the recent pharmacological advances. Eur J Med Chem. 2018;143:542\u201357. https:\/\/doi.org\/10.1016\/j.ejmech.2017.11.064.","journal-title":"Eur J Med Chem"},{"key":"3578_CR17","doi-asserted-by":"publisher","first-page":"104639","DOI":"10.1016\/j.bioorg.2021.104639","volume":"109","author":"P Yadav","year":"2021","unstructured":"Yadav P, Shah K. Quinolines, a perpetual, multipurpose scaffold in medicinal chemistry. Bioorg Chem. 2021;109:104639. https:\/\/doi.org\/10.1016\/j.bioorg.2021.104639.","journal-title":"Bioorg Chem"},{"issue":"2","key":"3578_CR18","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/s11101-015-9413-5","volume":"15","author":"SRM Ibrahim","year":"2016","unstructured":"Ibrahim SRM, Mohamed GA. Naturally occurring naphthalenes: Chemistry, biosynthesis, structural elucidation, and biological activities. Phytochem Rev. 2016;15(2):279\u201395. https:\/\/doi.org\/10.1007\/s11101-015-9413-5.","journal-title":"Phytochem Rev"},{"issue":"6","key":"3578_CR19","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1080\/14756360412331280473","volume":"19","author":"M Medarde","year":"2004","unstructured":"Medarde M, Maya ABS, P\u00e9rez-Melero C. Review Article naphthalene combretastatin analogues: Synthesis, cytotoxicity and antitubulin activity. J Enzyme Inhib Med Chem. 2004;19(6):521\u201340. https:\/\/doi.org\/10.1080\/14756360412331280473.","journal-title":"J Enzyme Inhib Med Chem"},{"issue":"7","key":"3578_CR20","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1016\/j.bmcl.2011.02.055","volume":"21","author":"Q Chen","year":"2011","unstructured":"Chen Q, Bryant VC, Lopez H, Kelly DL, Luo X, Natarajan A. 2,3-Substituted quinoxalin-6-amine analogs as antiproliferatives: A structure\u2013activity relationship study. Bioorg Med Chem Lett. 2011;21(7):1929\u201332. https:\/\/doi.org\/10.1016\/j.bmcl.2011.02.055.","journal-title":"Bioorg Med Chem Lett"},{"key":"3578_CR21","doi-asserted-by":"publisher","first-page":"130317","DOI":"10.1016\/j.molstruc.2021.130317","volume":"1236","author":"EA Fayed","year":"2021","unstructured":"Fayed EA, Ammar YA, Saleh MA, Bayoumi AH, Belal A, Mehany ABM, et al. Design, synthesis, antiproliferative evaluation, and molecular docking study of new quinoxaline derivatives as apoptotic inducers and EGFR inhibitors. J Mol Struct. 2021;1236:130317. https:\/\/doi.org\/10.1016\/j.molstruc.2021.130317.","journal-title":"J Mol Struct"},{"issue":"6","key":"3578_CR22","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.1016\/j.ejmech.2011.03.015","volume":"46","author":"MN Noolvi","year":"2011","unstructured":"Noolvi MN, Patel HM, Bhardwaj V, Chauhan A. Synthesis and in vitro antitumor activity of substituted quinazoline and quinoxaline derivatives: Search for anticancer agent. Eur J Med Chem. 2011;46(6):2327\u201346. https:\/\/doi.org\/10.1016\/j.ejmech.2011.03.015.","journal-title":"Eur J Med Chem"},{"issue":"6","key":"3578_CR23","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1016\/j.bmcl.2018.01.050","volume":"28","author":"J Choi","year":"2018","unstructured":"Choi J, Lee K, Kang M, Lim SK, Tai No K. silico discovery of quinoxaline derivatives as novel LRP5\/6-sclerostin interaction inhibitors. Bioorg Med Chem Lett. 2018;28(6):1116\u201321. https:\/\/doi.org\/10.1016\/j.bmcl.2018.01.050.","journal-title":"Bioorg Med Chem Lett"},{"issue":"12","key":"3578_CR24","doi-asserted-by":"publisher","first-page":"3215","DOI":"10.1002\/jhet.3716","volume":"56","author":"AH Bayoumi","year":"2019","unstructured":"Bayoumi AH, Ghiaty AH, Abd El-Gilil SM, Husseiny EM, Ebrahim MA. Exploration of quinoxaline derivatives as antimicrobial and anticancer agents. J Heterocycl Chem. 2019;56(12):3215\u201335. https:\/\/doi.org\/10.1002\/jhet.3716.","journal-title":"J Heterocycl Chem"},{"issue":"46","key":"3578_CR25","doi-asserted-by":"publisher","first-page":"34005","DOI":"10.1039\/d4ra06712f","volume":"14","author":"N Ryad","year":"2024","unstructured":"Ryad N, Elmaaty AA, Selim S, Almuhayawi MS, Al Jaouni SK, Abdel-Aziz MS, et al. Design and synthesis of novel 2-(2-(4-bromophenyl)quinolin-4-yl)-1,3,4-oxadiazole derivatives as anticancer and antimicrobial candidates: in vitro and in silico studies. RSC Adv. 2024;14(46):34005\u201326. https:\/\/doi.org\/10.1039\/d4ra06712f.","journal-title":"RSC Adv"},{"issue":"19","key":"3578_CR26","doi-asserted-by":"publisher","first-page":"e38105","DOI":"10.1016\/j.heliyon.2024.e38105","volume":"10","author":"V Shalini","year":"2024","unstructured":"Shalini V, Priyadarshini AN, Harsha KB, Vinay KDC, Darshini G, Chethan BS, et al. Novel quinoline-4-carboxamide derivatives potentiates apoptosis by targeting PDK1 to overcome chemo-resistance in colorectal cancer: Theoretical and experimental results. Heliyon. 2024;10(19):e38105. https:\/\/doi.org\/10.1016\/j.heliyon.2024.e38105.","journal-title":"Heliyon"},{"issue":"17","key":"3578_CR27","doi-asserted-by":"publisher","first-page":"4044","DOI":"10.3390\/molecules29174044","volume":"29","author":"A Zieba","year":"2024","unstructured":"Zieba A, Pindjakova D, Latocha M, Plonka-Czerw J, Kusmierz D, Cizek A, et al. Design, synthesis, and anticancer and antibacterial activities of quinoline-5-sulfonamides. Molecules. 2024;29(17):4044. https:\/\/doi.org\/10.3390\/molecules29174044.","journal-title":"Molecules"},{"issue":"16","key":"3578_CR28","doi-asserted-by":"publisher","first-page":"4899","DOI":"10.3390\/molecules26164899","volume":"26","author":"YF Guan","year":"2021","unstructured":"Guan YF, Liu XJ, Yuan XY, Liu WB, Li YR, Yu GX, et al. Design, synthesis, and anticancer activity studies of novel quinoline-chalcone derivatives. Molecules. 2021;26(16):4899. https:\/\/doi.org\/10.3390\/molecules26164899.","journal-title":"Molecules"},{"issue":"1","key":"3578_CR29","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1080\/14756366.2019.1690479","volume":"35","author":"G Wang","year":"2020","unstructured":"Wang G, Liu W, Gong Z, Huang Y, Li Y, Peng Z. Synthesis, biological evaluation, and molecular modelling of new naphthalene-chalcone derivatives as potential anticancer agents on MCF\u20137 breast cancer cells by targeting tubulin colchicine binding site. J Enzyme Inhib Med Chem. 2020;35(1):139\u201344. https:\/\/doi.org\/10.1080\/14756366.2019.1690479.","journal-title":"J Enzyme Inhib Med Chem"},{"issue":"1","key":"3578_CR30","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1080\/14756366.2021.1958213","volume":"36","author":"G Wang","year":"2021","unstructured":"Wang G, Liu W, Fan M, He M, Li Y, Peng Z. Design, synthesis and biological evaluation of novel thiazole-naphthalene derivatives as potential anticancer agents and tubulin polymerisation inhibitors. J Enzyme Inhib Med Chem. 2021;36(1):1693\u2013701. https:\/\/doi.org\/10.1080\/14756366.2021.1958213.","journal-title":"J Enzyme Inhib Med Chem"},{"key":"3578_CR31","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.bioorg.2017.11.017","volume":"76","author":"G Wang","year":"2018","unstructured":"Wang G, Qiu J, Xiao X, Cao A, Zhou F. Synthesis, biological evaluation and molecular docking studies of a new series of chalcones containing naphthalene moiety as anticancer agents. Bioorg Chem. 2018;76:249\u201357. https:\/\/doi.org\/10.1016\/j.bioorg.2017.11.017.","journal-title":"Bioorg Chem"},{"key":"3578_CR32","doi-asserted-by":"publisher","first-page":"104141","DOI":"10.1016\/j.bioorg.2020.104141","volume":"103","author":"G Wang","year":"2020","unstructured":"Wang G, Liu W, Peng Z, Huang Y, Gong Z, Li Y. Design, synthesis, molecular modeling, and biological evaluation of pyrazole-naphthalene derivatives as potential anticancer agents on MCF\u20137 breast cancer cells by inhibiting tubulin polymerization. Bioorg Chem. 2020;103:104141. https:\/\/doi.org\/10.1016\/j.bioorg.2020.104141.","journal-title":"Bioorg Chem"},{"issue":"7","key":"3578_CR33","doi-asserted-by":"publisher","first-page":"6669","DOI":"10.1021\/acsomega.2c07256","volume":"8","author":"D Osmaniye","year":"2023","unstructured":"Osmaniye D, Sa\u011fl\u0131k BN, Khalilova N, Levent S, Bayaz\u0131t G, G\u00fcl \u00dcD, et al. Design, synthesis, and biological evaluation studies of novel naphthalene-chalcone hybrids as antimicrobial, anticandidal, anticancer, and VEGFR-2 inhibitors. ACS Omega. 2023;8(7):6669\u201378. https:\/\/doi.org\/10.1021\/acsomega.2c07256.","journal-title":"ACS Omega"},{"issue":"6","key":"3578_CR34","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1007\/s00044-025-03418-0","volume":"34","author":"T Kamloon","year":"2025","unstructured":"Kamloon T, Senawong T, Senawong G, Namwan N, Kumboonma P, Somsakeesit L, et al. Exploring putative histone deacetylase inhibitors with antiproliferative activity of chrysin derivatives. Med Chem Res. 2025;34(6):1308\u201320. https:\/\/doi.org\/10.1007\/s00044-025-03418-0.","journal-title":"Med Chem Res"},{"issue":"9","key":"3578_CR35","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1111\/1759-7714.13925","volume":"12","author":"H Guo","year":"2021","unstructured":"Guo H, Ding H, Tang X, Liang M, Li S, Zhang J, et al. Quercetin induces pro-apoptotic autophagy via SIRT1\/AMPK signaling pathway in human lung cancer cell lines A549 and H1299 in vitro. Thorac Cancer. 2021;12(9):1415\u201322. https:\/\/doi.org\/10.1111\/1759-7714.13925.","journal-title":"Thorac Cancer"},{"issue":"8","key":"3578_CR36","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1080\/07357907.2021.1931875","volume":"39","author":"NM Abdel-Hamid","year":"2021","unstructured":"Abdel-Hamid NM, Fathy M, Koike C, Yoshida T, Okabe M, Zho K, et al. Identification of chemo and radio-resistant sub-population of stem cells in human cervical cancer HeLa cells. Cancer Invest. 2021;39(8):661\u201374. https:\/\/doi.org\/10.1080\/07357907.2021.1931875.","journal-title":"Cancer Invest"},{"issue":"38","key":"3578_CR37","doi-asserted-by":"publisher","first-page":"26926","DOI":"10.1074\/jbc.M113.490706","volume":"288","author":"BE Lauffer","year":"2013","unstructured":"Lauffer BE, Mintzer R, Fong R, Mukund S, Tam C, Zilberleyb I, et al. Histone deacetylase (HDAC) inhibitor kinetic rate constants correlate with cellular histone acetylation but not transcription and cell viability. J Biol Chem. 2013;288(38):26926\u201343. https:\/\/doi.org\/10.1074\/jbc.M113.490706.","journal-title":"J Biol Chem"},{"issue":"1","key":"3578_CR38","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1021\/acschembio.9b00714","volume":"15","author":"RR Asawa","year":"2020","unstructured":"Asawa RR, Gao C, Huang H, Wang C, Sorna V, Beier UH, et al. A comparative study of target engagement assays for HDAC1 inhibitors in cells. ACS Chem Biol. 2020;15(1):179\u201390. https:\/\/doi.org\/10.1021\/acschembio.9b00714.","journal-title":"ACS Chem Biol"},{"issue":"2","key":"3578_CR39","doi-asserted-by":"publisher","first-page":"317","DOI":"10.3390\/antiox12020317","volume":"12","author":"AP Zani","year":"2023","unstructured":"Zani AP, Zani CP, Din ZU, Rodrigues-Filho E, Ueda-Nakamura T, Garcia FP, et al. Dibenzylideneacetone induces apoptosis in cervical cancer cells through ROS-mediated mitochondrial damage. Antioxidants. 2023;12(2):317. https:\/\/doi.org\/10.3390\/antiox12020317.","journal-title":"Antioxidants"},{"issue":"4","key":"3578_CR40","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.3892\/or.2013.2288","volume":"29","author":"Y Porameesanaporn","year":"2013","unstructured":"Porameesanaporn Y, Uthaisang-Tanechpongtamb W, Jarintanan F, Jongrungruangchok S, Wongsatayanon BT. Terrein induces apoptosis in HeLa human cervical carcinoma cells through p53 and ERK regulation. Oncol Rep. 2013;29(4):1600\u20138. https:\/\/doi.org\/10.3892\/or.2013.2288.","journal-title":"Oncol Rep"},{"issue":"1","key":"3578_CR41","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1124\/mol.109.055178","volume":"76","author":"JM Wagner","year":"2009","unstructured":"Wagner JM, Karnitz LM. Cisplatin-induced DNA damage activates replication checkpoint signaling components that differentially affect tumor cell survival. Mol Pharmacol. 2009;76(1):208\u201314. https:\/\/doi.org\/10.1124\/mol.109.055178.","journal-title":"Mol Pharmacol"},{"issue":"4","key":"3578_CR42","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1016\/j.bmcl.2008.12.083","volume":"19","author":"SD Kattar","year":"2009","unstructured":"Kattar SD, Surdi LM, Zabierek A, Methot JL, Middleton RE, Hughes B, et al. Parallel medicinal chemistry approaches to selective HDAC1\/HDAC2 inhibitor (SHI-1:2) optimization. Bioorg Med Chem Lett. 2009;19(4):1168\u201372. https:\/\/doi.org\/10.1016\/j.bmcl.2008.12.083.","journal-title":"Bioorg Med Chem Lett"},{"issue":"13","key":"3578_CR43","doi-asserted-by":"publisher","first-page":"4014","DOI":"10.3390\/molecules27134014","volume":"27","author":"N Namwan","year":"2022","unstructured":"Namwan N, Senawong G, Phaosiri C, Kumboonma P, Somsakeesit L, Samankul A, et al. HDAC inhibitory and anti-cancer activities of curcumin and curcumin derivative CU17 against human lung cancer A549 cells. Molecules. 2022;27(13):4014. https:\/\/doi.org\/10.3390\/molecules27134014.","journal-title":"Molecules"},{"key":"3578_CR44","doi-asserted-by":"publisher","unstructured":"Crowley LC, Marfell BJ, Waterhouse NJ. Analyzing cell death by nuclear staining with Hoechst 33342. Cold Spring Harb Protoc. 2016;2016(8). https:\/\/doi.org\/10.1101\/pdb.prot087205. pdb.prot087205.","DOI":"10.1101\/pdb.prot087205"},{"issue":"10","key":"3578_CR45","doi-asserted-by":"publisher","first-page":"3142","DOI":"10.1016\/j.bmcl.2010.03.091","volume":"20","author":"JC Bressi","year":"2010","unstructured":"Bressi JC, Jennings AJ, Skene R, Wu Y, Melkus R, De Jong R, et al. Exploration of the HDAC2 foot pocket: Synthesis and SAR of substituted N-(2-aminophenyl)benzamides. Bioorg Med Chem Lett. 2010;20(10):3142\u201345. https:\/\/doi.org\/10.1016\/j.bmcl.2010.03.091.","journal-title":"Bioorg Med Chem Lett"},{"issue":"3","key":"3578_CR46","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.3390\/molecules27031088","volume":"27","author":"N Hangsamai","year":"2022","unstructured":"Hangsamai N, Photai K, Mahaamnart T, Kanokmedhakul S, Kanokmedhakul K, Senawong T, et al. Four new anthraquinones with histone deacetylase inhibitory activity from Ventilago denticulata roots. Molecules. 2022;27(3):1088. https:\/\/doi.org\/10.3390\/molecules27031088.","journal-title":"Molecules"},{"key":"3578_CR47","doi-asserted-by":"publisher","first-page":"42717","DOI":"10.1038\/srep42717","volume":"7","author":"A Daina","year":"2017","unstructured":"Daina A, Michielin O, Zoete V. SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep. 2017;7:42717. https:\/\/doi.org\/10.1038\/srep42717.","journal-title":"Sci Rep"},{"issue":"W1","key":"3578_CR48","doi-asserted-by":"publisher","first-page":"W422","DOI":"10.1093\/nar\/gkae236","volume":"52","author":"L Fu","year":"2024","unstructured":"Fu L, Shi S, Yi J, Wang N, He Y, Wu Z, et al. ADMETlab 3.0: An updated comprehensive online ADMET prediction platform enhanced with broader coverage, improved performance, API functionality and decision support. Nucleic Acids Res. 2024;52(W1):W422\u201331. https:\/\/doi.org\/10.1093\/nar\/gkae236.","journal-title":"Nucleic Acids Res"}],"container-title":["Medicinal Chemistry Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00044-026-03578-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00044-026-03578-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00044-026-03578-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T09:47:04Z","timestamp":1782380824000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00044-026-03578-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,28]]},"references-count":48,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["3578"],"URL":"https:\/\/doi.org\/10.1007\/s00044-026-03578-7","relation":{},"ISSN":["1054-2523","1554-8120"],"issn-type":[{"value":"1054-2523","type":"print"},{"value":"1554-8120","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,28]]},"assertion":[{"value":"10 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}}]}}